Mechanisms involved
This condition is explained through the mechanisms below. Each one is taught as ordinary physiology first.
Primary
Secondary / contributing
Immune cells involvedWho is actually in the tissue
Here the mast cell is not a bystander — it is the condition.
Selected cell
Mast cell
Tissue sentinel packed with histamine, tryptase and prostaglandin granules. When it degranulates it recruits and sensitizes nearby nerve endings.
Mast cells release mediators repeatedly in response to triggers that should be neutral: heat, friction, foods, hormones, stress.
Schematic drawings, not micrographs. Immune findings here describe mechanism and association; none of them are diagnostic tests.
What it is
Mast cell activation syndrome describes episodic, multi-system symptoms caused by mediator release, in the absence of a clonal mast-cell disorder. Consensus criteria require symptoms in two or more organ systems, objective evidence of mediator release where obtainable, and response to mediator-directed treatment.
How the mechanisms produce this
- Mediators act within minutes on vessels, gut, skin and airway, which is why episodes are fast, multi-system and short.
- Mediator half-lives are short and sampling windows narrow, so negative tryptase does not exclude the syndrome — and does not confirm it either.
- Estrogen upregulates mast-cell activity, so reactivity commonly tracks the cycle.
- Because mediators drop vascular tone, this mechanism can be the actual driver of an orthostatic picture.
What tends to help
- Trigger mapping over weeks, with a log, rather than pre-emptive elimination of everything.
- H1 plus H2 blockade trialled with a defined endpoint before adding stabilisers.
- Rule out the conditions that mimic it — clonal disease, carcinoid, thyroid, phaeochromocytoma.
- Treat sleep and deconditioning, which measurably lower the reactivity threshold.
Where the evidence is thin
Criteria are contested between specialist groups, and the broad criteria in wide circulation online overdiagnose substantially.